MeSH tree: C01.150.252.819.420
The rates of respondent dissatisfaction with current hidradenitis suppurativa (HS) treatment options are high, likely due to undertreatment with available therapies, according to a study published in the April issue of the ...
Apr 7, 2025
0
14
Children with obesity have increased rates of dermatologic conditions, according to a study published online Feb. 10 in Pediatric Dermatology.
Feb 26, 2025
0
17
The U.S. Food and Drug Administration has approved UCB's Bimzelx (bimekizumab-bkzx) for the treatment of adults with moderate-to-severe hidradenitis suppurativa.
Nov 26, 2024
0
27
Hidradenitis suppurativa, commonly referred to as HS, is a debilitating skin condition that causes chronic inflammation on the surface of the skin. This condition is characterized by painful bumps or boils that form under ...
Nov 20, 2024
0
31
University of Montreal and McGill University researchers in Canada have identified a significant association between hidradenitis suppurativa (HS) and higher risks of adverse pregnancy outcomes, as well as long-term health ...
For patients with hidradenitis suppurativa (HS), bimekizumab is safe and efficacious over two years, according to a study presented at the annual meeting of the European Academy of Dermatology and Venereology, held from Sept. ...
Oct 7, 2024
0
23
A pioneering study, presented at the European Academy of Dermatology and Venereology (EADV) Congress 2024, demonstrates the significant potential of semaglutide in treating hidradenitis suppurative (HS), a common and chronic ...
Sep 25, 2024
0
26
The University of Cincinnati's Robert Van Haren was featured in a MedCentral article discussing recent research that found smoking cessation significantly reduced the risk of developing hidradenitis suppurativa, a non-contagious ...
Sep 5, 2024
0
34
Bimekizumab is well tolerated and produces clinically meaningful responses in patients with hidradenitis suppurativa, according to a study published online May 22 in The Lancet.
May 30, 2024
0
20
Treatment of hidradenitis suppurativa (HS) with intravenous ertapenem is associated with improvement in clinical and inflammatory markers, according to a study published online Feb. 19 in JAMA Dermatology.
Feb 21, 2024
0
27
